- Home
- HYI vs JBIO Comparison
HYI vs JBIO Comparison
Compare HYI & JBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- JBIO
- Stock Information
- Founded
- HYI 2010
- JBIO 2024
- Country
- HYI United States
- JBIO United States
- Employees
- HYI N/A
- JBIO N/A
- Industry
- HYI Investment Managers
- JBIO
- Sector
- HYI Finance
- JBIO
- Exchange
- HYI Nasdaq
- JBIO NYSE
- Market Cap
- HYI 272.0M
- JBIO 290.1M
- IPO Year
- HYI N/A
- JBIO N/A
- Fundamental
- Price
- HYI $11.90
- JBIO $8.28
- Analyst Decision
- HYI
- JBIO Strong Buy
- Analyst Count
- HYI 0
- JBIO 2
- Target Price
- HYI N/A
- JBIO $15.50
- AVG Volume (30 Days)
- HYI 50.6K
- JBIO 397.1K
- Earning Date
- HYI 01-01-0001
- JBIO 08-05-2025
- Dividend Yield
- HYI 9.59%
- JBIO N/A
- EPS Growth
- HYI N/A
- JBIO N/A
- EPS
- HYI N/A
- JBIO N/A
- Revenue
- HYI N/A
- JBIO N/A
- Revenue This Year
- HYI N/A
- JBIO N/A
- Revenue Next Year
- HYI N/A
- JBIO N/A
- P/E Ratio
- HYI N/A
- JBIO N/A
- Revenue Growth
- HYI N/A
- JBIO N/A
- 52 Week Low
- HYI $10.99
- JBIO $1.61
- 52 Week High
- HYI $12.24
- JBIO $13.50
- Technical
- Relative Strength Index (RSI)
- HYI 45.70
- JBIO N/A
- Support Level
- HYI $11.87
- JBIO N/A
- Resistance Level
- HYI $12.00
- JBIO N/A
- Average True Range (ATR)
- HYI 0.06
- JBIO 0.00
- MACD
- HYI -0.02
- JBIO 0.00
- Stochastic Oscillator
- HYI 33.15
- JBIO 0.00
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About JBIO JADE BIOSCIENCES INC
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.